Xenon Pharmaceuticals, Inc.

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024. Fireside Chat Presentation Details: Date: Monday, October 7, 2024 Time: 11:40 am Eastern Time Webcast: Register here A live webcast of the company presentation will be available on the “ Investors ” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit . “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@xenon-pharma.com For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@xenon-pharma.com

VANCOUVER, British Columbia--( BUSINESS WIRE )--Life Sciences BC (LSBC) is pleased to announce new and returning members to the Board of Directors following its Annual General Meeting (AGM) held on September 18, 2024. The Board of Directors is comprised of life sciences leaders aligned with LSBC’s vision of a thriving sector within the province. AGM & Board Meeting Announcements Anne Stevens, VP of Business Development at AbCellera was elected as Chair, Ali Ardakani, Founder and Managing Director of Novateur Ventures Inc. was elected as Past Chair, and Rajveer Hundal, Partner at PWC Canada was re-elected as Treasurer. “Ali Ardakani has been a phenomenal leader for LSBC during his term as Board Chair over the past two years. I would like to thank him for everything he has done not only for LSBC but for the entire sector,” said Wendy Hurlburt, LSBC President & CEO. “Ali will continue his work with LSBC as Past Chair and we are excited to welcome Anne Stevens as our incoming Board Chair.” LSBC welcomes Sherry Aulin, CFO of Xenon Pharmaceuticals and Tom Frohlich, Former COO of Chinook Therapeutics as new Board Directors, who were each elected to three-year terms. LSBC would like to thank Board Directors continuing their terms: Max Blouw, Kevin Chaplin, Suzanne Gill, David Helliwell, Wendy Hurlburt, Bev Holmes, Dr. Lana Janes, Dr. David Llewellyn, Michael R. Martin, Scott Phillips, David Poon, and Dr. Peter Zandstra. At the Board Meeting following the AGM, Joseph Garcia, Hector MacKay-Dunn, KC, and Roger Kuypers received renewed one-year appointments as Board Observers. To see the full list of Life Sciences BC’s Board of Directors, please visit: https://lifesciencesbc.ca/about-us/board-directors/ LSBC Board Directors – Executive Committee Chair: Anne Stevens, VP Business Development, AbCellera Past Chair: Ali Ardakani, Founder and Managing Director, Novateur Ventures Inc. Treasurer: Rajveer Hundal, Partner, PWC Canada LSBC Board Directors Sherry Aulin, CFO, Xenon Pharmaceuticals Max Blouw, Past President, Research Universities Council of British Columbia Kevin Chaplin, CEO, Kardium Tom Frohlich, Life Sciences Executive Leader & Former COO, Chinook Therapeutics Suzanne Gill, President & CEO, Genome British Columbia David Helliwell, Co-Founder and Executive Board Chair, Thrive Health Bev Holmes, President & CEO, Michael Smith Health Research BC Wendy Hurlburt, President & CEO, Life Sciences BC Dr. Lana Janes, Co-Founder & COO, Abdera Dr. David Llewellyn, PhD, MBA, Chief Strategy Officer, STEMCELL Technologies Michael R. Martin, Life Sciences Executive Leader, Founder & Former COO / Business Officer, Aurinia Pharmaceuticals Scott Phillips, Founder & President, Starfish Medical David Poon, Life Sciences Business Executive Dr. Peter Zandstra, Director, UBC School of Biomedical Engineering & Michael Smith Labs LSBC Board Observers Joseph Garcia, Partner, Blake, Cassels & Graydon LLP Roger Kuypers, Partner, Fasken, Martineau, Dumoulin LLP Hector MacKay-Dunn, KC, Senior Partner, Farris, Vaughan, Wills & Murphy LLP Past Board Members LSBC would like to thank our outgoing Board Directors for their service and leadership over the past years. Jennifer Cudlipp, President & CEO, BACAS Family Wines Bob Dawson, National Director, Access and Government Relations, Pfizer Canada Peter Simpson, Proprietor, Third Quarter Consulting About Life Sciences BC Life Sciences BC is a not-for-profit, non-government industry association that supports and represents British Columbia’s life sciences community through numerous local, national, and international initiatives. We nurture economic development in the province through leadership, facilitation of investment and partnering, advocacy, and promotion of our world-class life sciences sector. Throughout the year, Life Sciences BC initiates a range of programs and projects designed to bolster the life sciences sector. These initiatives encompass activities such as advocating for public policies, fostering connections between our local organizations and the global industry, enhancing our sector's international visibility, and facilitating investments and global partnerships.

Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster presentations at the 15th European Epilepsy Congress (EEC) taking place in Rome, Italy. Azetukalner, a novel, potent Kv7 channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage development for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS) and major depressive disorder (MDD). “We are excited for this opportunity to engage with leading epileptologists at EEC in Rome and share long-term azetukalner data from our ongoing X-TOLE open-label extension study. Azetukalner represents the only Kv7 potassium channel opener in clinical development that is supported by Phase 2b data as well as long-term efficacy and safety data in epilepsy patients,” stated Dr. Christopher Kenney, Chief Medical Officer of Xenon. “These data are particularly impressive given the baseline disease severity, with patients who are out to 30 months in the open-label extension study showing a greater than 90% reduction in median monthly seizure frequency, while approximately one in four patients on azetukalner for at least two years in the OLE have experienced a period of seizure freedom of a year or longer.” Dr. Kenney continued, “We are also presenting patient-reported survey data illustrating the substantial burden of illness for people living with epilepsy, with reduced quality of life, high seizure frequency and fatigue, as well as other comorbidities such as anxiety and depression, further underscoring the need for new medications to help people living with epilepsy.” Presentations at EEC: Poster #P282: Azetukalner (XEN1101), a Novel, Potent Kv7 Potassium Channel Opener: Interim Data From an Ongoing, Long‑Term, Open‑Label Extension of a Phase 2b Study (X‑TOLE) in Adults With Focal Onset SeizuresPresenter: Jacqueline A. French, New York University Grossman School of Medicine and NYU Langone Health, New York, NYSession Times: Daily from 1:30-3:00 pm CEST Poster #P281: Long-term, Quality of Life in Epilepsy Inventory-31 (QOLIE-31) Improvements in Adults With Focal Onset Seizures Treated With Azetukalner (XEN1101) in an Ongoing, Open-Label Extension of a Phase 2b study (X-TOLE)Presenter: Christian Brandt, Bethel Epilepsy Centre, Mara Hospital, University Hospital for Epileptology, Bielefeld, GermanySession Times: Daily from 1:30-3:00 pm CESTPoster Tour: S2 Clinical Neurophysiology/Drug Therapy Poster #P406: Non-seizure Symptoms, Mental Health Comorbidities, and Quality of Life in Patients Reporting Focal Onset SeizuresPresenter: Cynthia Harden, Xenon Pharmaceuticals Inc. Session Times: Daily from 1:30-3:00 pm CEST Posters will be available for viewing at the conference from Sunday, September 8 until Tuesday, September 10 at 4:00 pm CEST and will be added to the Xenon website consistent with conference guidelines. Xenon is also hosting a Scientific Exhibit at location SE1 and Booth #346. About Xenon Pharmaceuticals Inc.Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com. About the Azetukalner Phase 3 Epilepsy ProgramXenon’s Phase 3 epilepsy program includes three ongoing Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the double-blind period (DBP) of azetukalner compared to placebo. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the DBP of azetukalner compared to placebo. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs; and our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@xenon-pharma.com For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@xenon-pharma.com